TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

Benzinga Logo Benzinga By Vandana Singh
AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

AbbVie reported strong Q3 2025 financial results with $15.78 billion in sales, increased dividend to $1.73 per share, and raised fiscal 2025 earnings guidance to $10.61-$10.65 per share, driven by robust immunology portfolio growth.

Insights
ABBV   positive

Strong sales growth of 9.1%, significant immunology portfolio performance (Skyrizi sales up 46.8%), raised earnings guidance, and increased quarterly dividend indicate robust financial health and strategic momentum